Daling Janet R, Madeleine Margaret M, Schwartz Stephen M, Shera Katherine A, Carter Joseph J, McKnight Barbara, Porter Peggy L, Galloway Denise A, McDougall James K, Tamimi Hisham
Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Seattle, Washington 98109-1024, USA.
Gynecol Oncol. 2002 Feb;84(2):263-70. doi: 10.1006/gyno.2001.6502.
Little is known about the etiology of in situ or invasive squamous cell cancer of the vagina. It is thought that some vaginal cancers may have the same etiology as cervical cancer. It is also not known whether in situ and invasive vaginal cancer share the same etiologic factors. We conducted a study to evaluate risk factors for in situ and invasive vaginal cancer and their potential relationship to prior exposure to human papillomaviruses (HPV).
A population-based case-control study included 156 women with squamous cell in situ or invasive vaginal cancer diagnosed between January 1981 and June 1998 and 2041 control women identified through random-digit dialing in western Washington state. Cases and controls were interviewed in person and provided blood samples; archival tumor tissue was retrieved for cases. Blood samples were tested for antibodies to HPV, and tumor tissue was tested for HPV DNA.
Women with vaginal cancer were more likely to have five or more lifetime sexual partners (OR = 3.1, 95% CI 1.9 to 4.9), to have an early age at first intercourse (<17 years OR = 2.0, 95% CI 1.2 to 3.5), and to be current smokers at diagnosis (OR = 2.1, 95% CI 1.4 to 3.1) than control women. Approximately 30% of all cases had been treated for a prior anogenital tumor, most often of the cervix. Prior hysterectomy was a risk factor only among women who had no history of prior anogenital cancer (OR = 3.9 95% CI 2.5 to 6.1). Antibodies to HPV16 L1 were strongly related to risk of vaginal cancer (OR = 4.3, 95% CI 3.0 to 6.2). We detected HPV DNA in tumor blocks from over 80% of the patients with in situ and 60% of the patients with invasive cancers.
In situ and invasive vaginal neoplasia have many of the same risk factors as cervical cancer, including a strong relationship to HPV infection. Women who have been treated for a prior anogenital cancer, particularly of the cervix, have a high relative risk, although low absolute risk, of being diagnosed with vaginal cancer.
阴道原位或浸润性鳞状细胞癌的病因知之甚少。人们认为一些阴道癌可能与宫颈癌病因相同。原位和浸润性阴道癌是否共享相同的病因因素也不清楚。我们开展了一项研究,以评估原位和浸润性阴道癌的危险因素及其与既往感染人乳头瘤病毒(HPV)的潜在关系。
一项基于人群的病例对照研究纳入了1981年1月至1998年6月期间诊断为鳞状细胞原位或浸润性阴道癌的156名女性,以及通过华盛顿州西部随机数字拨号确定的2041名对照女性。对病例和对照进行了面对面访谈并采集了血样;为病例检索了存档肿瘤组织。检测血样中的HPV抗体,并检测肿瘤组织中的HPV DNA。
与对照女性相比,阴道癌女性更有可能有5个或更多终身性伴侣(比值比[OR]=3.1,95%置信区间[CI]1.9至4.9)、首次性交年龄早(<17岁,OR=2.0,95%CI 1.2至3.5),以及在诊断时为当前吸烟者(OR=2.1,95%CI 1.4至3.1)。所有病例中约30%曾接受过既往肛门生殖器肿瘤治疗,最常见的是宫颈癌。既往子宫切除术仅在无既往肛门生殖器癌病史的女性中是一个危险因素(OR=3.9,95%CI 2.5至6.1)。HPV16 L1抗体与阴道癌风险密切相关(OR=4.3,95%CI 3.0至6.2)。我们在超过80%的原位癌患者和60%的浸润癌患者的肿瘤组织块中检测到了HPV DNA。
原位和浸润性阴道肿瘤与宫颈癌有许多相同的危险因素,包括与HPV感染密切相关。既往接受过肛门生殖器癌治疗的女性,尤其是宫颈癌患者,被诊断为阴道癌的相对风险较高,尽管绝对风险较低。